<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010707</url>
  </required_header>
  <id_info>
    <org_study_id>202104092</org_study_id>
    <nct_id>NCT05010707</nct_id>
  </id_info>
  <brief_title>Transgender Estradiol Affirming Therapy</brief_title>
  <acronym>TREAT</acronym>
  <official_title>Effectiveness and Safety of Different Estradiol Replacement Therapies in Transgender Female</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label, pilot, randomized clinical trial is to evaluate the&#xD;
      effectiveness, safety and tolerability of estrogen use in transgender female and the degree&#xD;
      of testosterone suppression achieved in this population when placed on gender affirming&#xD;
      pharmacological therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transgender patients suffer from poor mental and medical health outcomes compared to their&#xD;
      cisgender peers. Given the widespread acknowledgment of the health care needs of transgender&#xD;
      people, priority should be given to those actions that will ensure safe and appropriate care&#xD;
      in health centers.&#xD;
&#xD;
      The current hormone therapy is not uniform and depends on the health care system, cost&#xD;
      considerations, and differences in the regional availability of estrogens and antiandrogens.&#xD;
      A typical regimen includes estrogen to provide feminizing effects in conjunction with therapy&#xD;
      to block testosterone (antiandrogens or gonadotropin-releasing hormone [GnRH] analogs).&#xD;
      Estrogen also inhibits testosterone secretion.&#xD;
&#xD;
      Ethinyl estradiol was previously the mainstay of most estrogen-directed therapies; this is no&#xD;
      longer the case due to its increased risk of cardiovascular death and increased incidence of&#xD;
      deep venous thrombosis. 17-beta estradiol, which can be provided in tablet, patch, and&#xD;
      injection, is currently the preferred formulation.&#xD;
&#xD;
      This open label, pilot, randomized clinical trial will evaluate the effectiveness and safety&#xD;
      of gender affirming hormone therapy with estrogen and the degree of testosterone suppression&#xD;
      achieved in transgender female patients when placed on daily sublingual 17-beta estradiol,&#xD;
      twice daily sublingual 17-beta estradiol, or transdermal 17-beta estradiol. All patients will&#xD;
      also receive spironolactone as antiandrogen.&#xD;
&#xD;
      One of the major complications from estradiol GAHT is thromboembolism. The investigators will&#xD;
      also determine the effects of the different estradiol regimens on thrombosis markers. These&#xD;
      studies will be the first to determine if the dosing regimen of estradiol affects risk&#xD;
      markers in transgender women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants who agreed to be in the study will undergo block randomization into three groups:&#xD;
daily sublingual 17 beta estradiol&#xD;
twice daily sublingual 17 beta estradiol&#xD;
transdermal 17 beta estradiol&#xD;
All patients will also receive spironolactone as antiandrogen.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of testosterone suppression by measuring total testosterone level in transgender female patients undergoing hormonal affirming therapy</measure>
    <time_frame>Change from baseline total testosterone level at 6,12,18, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coagulation factors II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance in transgender female patients undergoing</measure>
    <time_frame>Change from baseline factor II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance level at 6,12,18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>von Willebrand factor in transgender female patients undergoing</measure>
    <time_frame>Change from baseline von Willebrand factor antigen level at 6,12,18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Llipid panel</measure>
    <time_frame>Changes from baseline lipid panel at 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance</measure>
    <time_frame>Change from baseline HOMA-IR at 6,12,18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Transgenderism</condition>
  <arm_group>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels&#xD;
All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.&#xD;
All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.&#xD;
Spironolactone will be started at 50 mg daily and will increase to standard dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels&#xD;
All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.&#xD;
Spironolactone will be started at 50 mg daily and will increase to standard dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal patch</intervention_name>
    <description>Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels</description>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pro-thrombotic markers</intervention_name>
    <description>Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.</description>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Metabolic markers</intervention_name>
    <description>Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.</description>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hormone Profile</intervention_name>
    <description>Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.</description>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Tablet</intervention_name>
    <description>Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels</description>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <other_name>Once daily dosing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Tablet</intervention_name>
    <description>Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels</description>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
    <other_name>Twice daily dosing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.</description>
    <arm_group_label>Daily sublingual estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Transdermal estradiol plus spironolactone</arm_group_label>
    <arm_group_label>Twice daily sublingual estradiol plus spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female transgender patients between the ages of 18 to 30 years of age who are seen at&#xD;
             the Washington University Transgender Center. Patients must have met the eligibility&#xD;
             and readiness criteria for gender-affirming hormone therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GnRH agonist for the last 12 months&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  Dyslipidemia requiring treatment&#xD;
&#xD;
          -  Cigarette smoking&#xD;
&#xD;
          -  Body mass index &gt;30 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginger Nicol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Cortez, MD</last_name>
    <phone>314-286-2339</phone>
    <email>scortez@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University Transgender Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Cortez, MD</last_name>
      <phone>314-286-2339</phone>
      <email>scortez@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016 Dec;5(6):877-884. doi: 10.21037/tau.2016.09.04. Review.</citation>
    <PMID>28078219</PMID>
  </reference>
  <reference>
    <citation>Kaltiala-Heino R, Bergman H, Työläjärvi M, Frisén L. Gender dysphoria in adolescence: current perspectives. Adolesc Health Med Ther. 2018 Mar 2;9:31-41. doi: 10.2147/AHMT.S135432. eCollection 2018. Review.</citation>
    <PMID>29535563</PMID>
  </reference>
  <reference>
    <citation>Connolly MD, Zervos MJ, Barone CJ 2nd, Johnson CC, Joseph CL. The Mental Health of Transgender Youth: Advances in Understanding. J Adolesc Health. 2016 Nov;59(5):489-495. doi: 10.1016/j.jadohealth.2016.06.012. Epub 2016 Aug 17. Review.</citation>
    <PMID>27544457</PMID>
  </reference>
  <reference>
    <citation>Hamidi O, Davidge-Pitts CJ. Transfeminine Hormone Therapy. Endocrinol Metab Clin North Am. 2019 Jun;48(2):341-355. doi: 10.1016/j.ecl.2019.02.001. Epub 2019 Mar 23. Review.</citation>
    <PMID>31027544</PMID>
  </reference>
  <reference>
    <citation>Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Apr;164(4):635-42. doi: 10.1530/EJE-10-1038. Epub 2011 Jan 25.</citation>
    <PMID>21266549</PMID>
  </reference>
  <reference>
    <citation>Angus LM, Nolan BJ, Zajac JD, Cheung AS. A systematic review of antiandrogens and feminization in transgender women. Clin Endocrinol (Oxf). 2021 May;94(5):743-752. doi: 10.1111/cen.14329. Epub 2020 Oct 5. Review.</citation>
    <PMID>32926454</PMID>
  </reference>
  <reference>
    <citation>Spanos C, Bretherton I, Zajac JD, Cheung AS. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. World J Diabetes. 2020 Mar 15;11(3):66-77. doi: 10.4239/wjd.v11.i3.66.</citation>
    <PMID>32180895</PMID>
  </reference>
  <reference>
    <citation>Bagot CN, Marsh MS, Whitehead M, Sherwood R, Roberts L, Patel RK, Arya R. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010 Aug;8(8):1736-44. doi: 10.1111/j.1538-7836.2010.03953.x. Epub 2010 Jun 14.</citation>
    <PMID>20553380</PMID>
  </reference>
  <reference>
    <citation>Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658. Erratum in: J Clin Endocrinol Metab. 2018 Feb 1;103(2):699. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2758-2759.</citation>
    <PMID>28945902</PMID>
  </reference>
  <reference>
    <citation>Bao AM, Liu RY, van Someren EJ, Hofman MA, Cao YX, Zhou JN. Diurnal rhythm of free estradiol during the menstrual cycle. Eur J Endocrinol. 2003 Feb;148(2):227-32.</citation>
    <PMID>12590642</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ginger E Nicol</investigator_full_name>
    <investigator_title>Associate Professor of Child &amp; Adolescent Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Transgender female</keyword>
  <keyword>Gender affirming hormone therapy</keyword>
  <keyword>Estrogen therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

